Key Takeaways
- Core business delivered 12% growth despite a messy quarter: reported revenue grew 14% YoY to Rs. 5,260 crore, but the underlying story is the non-COVID portfolio's momentum, especially in India and U.S. respiratory.
- One-time charges obscured profitability: Rs. 200 crore in charges (COVID inventory, South Africa restructuring, Avenue impairment, Sri Lanka FX) dragged reported PAT to Rs. 362 crore; adjusted PAT was nearly Rs. 610 crore, and adjusted core operating margins expanded 100 bps YoY to 18%.
- India franchise crossed a milestone: One-India business surpassed $1 billion in domestic branded prescription, growing 21% (15% adjusted for COVID), while consumer health reached EBITDA breakeven.
- U.S. respiratory engine is firing: Core formulation sales hit a multi-quarter high of $160 million, with the respiratory franchise growing 21% QoQ, offsetting price erosion elsewhere.
- What to watch next quarter: Whether the H2FY23 complex launch wave (Advair, Abraxane, Revlimid) stays on track, the pace of margin recovery toward the 21%+ guided range, and how much of the elevated procurement and freight costs persist.
India Business: The Growth Engine
- Branded prescription dominance: Sustained market-beating growth per IQVIA data; chronic portfolio delivered a 13% CAGR over FY18-22, expanding its share of core chronic to core branded prescription by nearly 750 bps over four years. Growth in chronic is largely volume-driven because Cipla was never historically strong in cardio and diabetes and built that presence over the last four years in dermatology, cardiovascular, and diabetes.
- Trade generics momentum: Strong demand traction for flagship brands with strong order flow across regions; FY22 growth was comfortably in double digits and higher than the market, though the portfolio skews more acute.
- Consumer health turnaround: Achieved EBITDA breakeven in FY22 through focused growth-linked investments and top-line leverage; management wants to grow sustainably from this breakeven position in FY23.
- Growth hierarchy: The highest growth within India came from the consumer business, followed by branded prescription, then trade generics, which was also significantly comfortable in double digits and higher than the market.
- COVID portfolio context: Management considers only products exclusively used for COVID as part of the COVID portfolio; antibiotics that sold more broadly are kept within the base business. The COVID contribution to India revenue was in the 5-10% range.
Vohra: "We are quite clear, I think we would like to see very high growth, better than market for the non-COVID portfolio. And I think our business momentum is very strong across all the 3 businesses."
U.S. Business: Respiratory & Complex Generics Pipeline
- Quarterly performance: Core formulation sales reached a multi-quarter high of $160 million, driven by strong traction in respiratory assets and contribution from the peptide portfolio, which offset price erosion in other parts of the portfolio. Full-year U.S. revenue was $594 million.
- Respiratory franchise: Grew 21% QoQ and 28% for the full year. Albuterol market share expanded to almost 22%, overachieving internal expectations for a product where Cipla launched as the third or fourth variant.
- Advair opportunity: The file is under active review at the FDA; the last query, received 4-6 months ago, was mostly around CMC. A facility inspection is pending because this is Cipla's first DPI product. Management is hoping for an H2FY23 launch and is "quite bullish," noting that 50% of the market is still branded, a sizable opportunity for all generic players.
- Abraxane: Hoping for a second-half launch; no specific FDA inspection date yet, but inspections have started in India significantly and management hopes to be audited soon.
- Generic Revlimid: Cipla expects to be in the second-half launch wave among those launching after the first wave, targeting strengths where exclusivity is ending.
- Lanreotide progress: On track with internal targets and currently in the time period for price listing and reimbursement listing; double-digit market share by year-end is "possible."
- Pipeline depth: Two respiratory products filed and not yet in the market, one in the clinic, and hopefully another entering the clinic later this year. One peptide injectable should be filed in fiscal '23.
Vohra: "We have overachieved what we thought we could do with albuterol, which was again a market category where we were launching as probably the third or the fourth variant of albuterol in this market. ... we've consistently tried to gain share there. So, I think those share conversions happen. It's a matter of time. And we're quite bullish about it."
Margins: One-Time Hits Mask Underlying Expansion
- Reported vs. adjusted: Reported PAT of Rs. 362 crore (6.9% of sales) included Rs. 70 crore impairment on the Avenue investment, Rs. 42 crore in FOREX loss on Sri Lankan receivables, and Rs. 200 crore in total one-time charges. Adjusted PAT was nearly Rs. 610 crore (11% of sales).
- One-time charge breakdown: Rs. 160 crore inventory charge in the gross margin line for the COVID portfolio, Rs. 20 crore in one-time operating expenses for COVID, and Rs. 20 crore for restructuring in the South African business.
- Gross margin: Reported at 59.2%, with an approximate 300 bps impact from the COVID inventory charge.
- Adjusted core operating margins: Expanded 100 bps YoY to 18%, despite reverse seasonality in the business mix, elevated procurement and freight costs, and higher R&D investments (clinical trials for one respiratory asset added Rs. 45 crore YoY).
- Procurement and freight impact: Approximately 50-70 bps on a full-year basis, not including power costs; part of the impact will be seen going forward because some is already in inventory. The Ukraine crisis worsened the situation, with the materiality of crude price swings hitting more in Q4 than before.
- R&D spend: At 6.1% of sales (Rs. 322 crore) in Q4, driven by assets progressing in clinical trials and portfolio development; expected to remain between 6% and 7% for FY23.
- Other expenses step-up: Higher sequentially because India business had more expenses than usual in Q4 (a respiratory quarter), spending was deferred from Q3 due to COVID, and R&D was higher as trials started.
SAGA & International Markets: Steady Amid Volatility
- SAGA performance: 8% YoY growth in dollar terms; South Africa private business grew 17% in local currency, with diversified growth across the base business and new launches. Cipla maintained its #3 position with 7.5% market share.
- International markets: Maintained scale at $385 million for the full year, with 4% growth in Q4. DTM franchises delivered strong double-digit growth, offsetting emerging market volatility and muted B2B demand in Europe.
- Sri Lanka exposure: A Rs. 45 crore accounting provision was taken for currency loss in value on receivables from the subsidiary; the charge sits in the other income line, reducing it.
- Emerging market pricing: Companies try to index pricing based on currencies, but even when some cost is passed on, currency depreciation takes it away, so the net effect keeps margins neutral rather than providing a benefit from price increases.
Capital Allocation: Cash-Rich and Hunting in India
- Cash position: Cipla has reached Rs. 4,000 crore of cash, a sharp turnaround from being a net-debt company two years prior, driven by strong cash flow generation.
- M&A strategy: Focus will continue to be on India and some other strong markets; cash can be borrowed or drawn from internal accruals. The objective is to support the CapEx program and buy assets in India.
- Deal size and rationale: Anything in the Rs. 200 crore to Rs. 500 crore range in sale is attractive if it fulfills a strategic need; management is looking for assets that create a 7- to 10-year presence.
- U.S. opportunity by FY25: The $300 million to $500 million revenue opportunity is largely from the organic pipeline where work has already been done through the P&L; it does not include any acquisitions.
Vohra: "I'm happy that we are in this situation because 2 years back, we were a net debt company. So, with our strong cash flow generation, today we have reached a point where we have Rs. 4,000 crore of cash."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India non-COVID growth | Grow "very high," better than market across all three businesses | FY23 |
| Operating margin | Upwards of 21%, in the 21% to 22% range, factoring in high commodity and procurement inflation | FY23 |
| Operating margin without Advair | Can still deliver 21%+ even if Advair does not launch this year | FY23 |
| R&D expense | Between 6% and 7% of sales | FY23 |
| Advair launch | Hoping for launch, pending facility inspection | H2FY23 |
| Abraxane launch | Hoping for launch, pending FDA audit | H2FY23 |
| Generic Revlimid launch | In the second-half launch wave for strengths where exclusivity ends | H2FY23 |
| Peptide injectable filing | One peptide injectable to be filed | FY23 |
| India consumer health | Grow sustainably from EBITDA breakeven | FY23 |
| Complex generics filings | Filings in complex generics, including peptide injectables, shall continue | FY23 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹5,260 cr, +14% YoY |
| Core revenue growth (ex-COVID) | 12% YoY for the quarter and full year |
| Reported gross margin | 59.2%, includes ~300 bps impact from COVID inventory charge |
| Reported EBITDA | ₹763 cr, 14.5% of sales |
| Adjusted EBITDA (ex-one-time charges) | ₹960 cr, 18%+ margin, +100 bps YoY |
| Adjusted EBITDA margin guidance (FY23) | 21% to 22% range |
| Reported PAT | ₹362 cr, 6.9% of sales |
| Adjusted PAT (ex-one-off items) | ~₹610 cr, 11% of sales |
| Effective tax rate (quarter) | 15.9%; full year ETR 26.7% |
| R&D spend | 6.1% of sales, ₹322 cr |
| One-India business growth | 21% YoY; 15% adjusted for COVID portfolio |
| India consumer health revenue (FY22) | Crossed ₹500 cr, achieved EBITDA breakeven in FY22 |
| U.S. core formulation sales | $160 mn, multi-quarter high |
| U.S. full year revenue | $594 mn |
| U.S. respiratory franchise growth | 21% QoQ, 28% for full year |
| SAGA region growth | 8% YoY in dollar terms |
| South Africa private business growth | 17% YoY in local currency |
| South Africa market share | 7.5%, third position |
| International markets revenue (full year) | $385 mn, +4% YoY for the quarter |
| Pretax return on invested capital | Over 21.6% |
| Net cash position | Net cash positive as of March 2022 |
| Cash on balance sheet | ₹4,000 cr |
| One-time charges | ₹200 cr: ₹160 cr COVID inventory charge, ₹20 cr COVID opex, ₹20 cr South Africa restructuring |
| Sri Lanka FOREX loss | ₹42 cr on outstanding receivables |
| Impairment charge (Avenue investment) | ~₹70 cr |
| Albuterol market share | ~22% |
| Freight and procurement cost impact | ~50 to 70 bps broadly on full-year basis |
| U.S. incremental revenue opportunity by FY25 | $300 mn to $500 mn, from organic pipeline |